company background image
STOK

Stoke Therapeutics NasdaqGS:STOK Stock Report

Last Price

US$7.16

Market Cap

US$282.3m

7D

-2.5%

1Y

-64.5%

Updated

05 Dec, 2022

Data

Company Financials +
STOK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

STOK Stock Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.

Stoke Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Stoke Therapeutics
Historical stock prices
Current Share PriceUS$7.16
52 Week HighUS$26.60
52 Week LowUS$6.88
Beta0.51
1 Month Change-38.75%
3 Month Change-50.28%
1 Year Change-64.47%
3 Year Change-73.59%
5 Year Changen/a
Change since IPO-72.00%

Recent News & Updates

Recent updates

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Nov 18
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Shareholder Returns

STOKUS BiotechsUS Market
7D-2.5%4.2%1.5%
1Y-64.5%-7.4%-14.9%

Return vs Industry: STOK underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: STOK underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is STOK's price volatile compared to industry and market?
STOK volatility
STOK Average Weekly Movement12.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: STOK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: STOK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014102Ed Kayehttps://www.stoketherapeutics.com

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.

Stoke Therapeutics, Inc. Fundamentals Summary

How do Stoke Therapeutics's earnings and revenue compare to its market cap?
STOK fundamental statistics
Market CapUS$282.32m
Earnings (TTM)-US$99.86m
Revenue (TTM)US$9.14m

30.9x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STOK income statement (TTM)
RevenueUS$9.14m
Cost of RevenueUS$0
Gross ProfitUS$9.14m
Other ExpensesUS$109.00m
Earnings-US$99.86m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.53
Gross Margin100.00%
Net Profit Margin-1,092.92%
Debt/Equity Ratio0%

How did STOK perform over the long term?

See historical performance and comparison